Page 11 - Nasdaq Obsv News Today : Breaking News, Live Updates & Top Stories | Vimarsana

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International...

ObsEva SA (NASDAQ:OBSV – Get Rating) has been given an average rating of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages […]

ObsEva (NASDAQ:OBSV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA […]

-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am...

Investment analysts at Canaccord Genuity Group initiated coverage on shares of ObsEva (NASDAQ:OBSV – Get Rating) in a report issued on Tuesday, The Fly reports. The firm set a “buy” rating and a $12.00 price target on the stock. Other equities analysts have also recently issued reports about the company. StockNews.com raised ObsEva from a […]